Default: Journal of the National Comprehensive Cancer Network : JNCCN

ISSN: 1540-1405

Journal Home

Journal Guideline

Journal of the National Comprehensive Cancer Network : JNCCN Q1 Unclaimed

Cold Spring Publishing LLC United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Journal of the National Comprehensive Cancer Network : JNCCN is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 150. It has an SJR impact factor of 4,102 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 4,102.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Journal of the National Comprehensive Cancer Network : JNCCN

4,102

SJR Impact factor

150

H Index

200

Total Docs (Last Year)

611

Total Docs (3 years)

7359

Total Refs

6158

Total Cites (3 years)

523

Citable Docs (3 years)

10.66

Cites/Doc (2 years)

36.8

Ref/Doc

Comments

No comments ... Be the first to comment!



Best articles by citations

VATS Versus Open Surgery for Lung Cancer Resection: Moving Beyond the Incision

View more

HSR20-085: Real-World Study of Factors Associated With Breast Conserving Surgery for Females Diagnosed With Early Stage Breast Cancer

View more

HSR20-087: Prevalence and Correlates of Psychological Distress in Patients Enrolling on Phase I Clinical Trials Using the NCCN Distress Thermometer and Problem List

View more

HSR20-088: Clinical Impact of Adherence to NCCN Biomarker Testing Guidelines on Survival for Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer

View more

HSR20-090: Current Utilization of Genomic Testing and Barriers to Optimal Patient Care: A Targeted Literature Review

View more

HSR20-091: Bridge to Good Living: Outcomes and Financial Implications of a Lung Cancer Survivorship Program in West Virginia

View more

HSR20-095: Progression-Free Survival, Overall Survival, and Tumor Response for Patients Diagnosed With Small Cell Lung Cancer Who Received First-Line Systemic Therapy

View more

HSR20-099: Cost Comparison of PARP Inhibitors in Women With Ovarian Cancer (OC) in the US HealthCare Market

View more

HSR20-100: Results From a Pilot Study Examining the Impact of Distress Screening and Referral on Cancer Patient Cost and Health Care Utilization

View more

HSR20-101: Real-World Chemoradiotherapy Use Among Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Retrospective Observational Study

View more

HSR20-102: Quality Outcomes in Colon Cancer

View more

The State of Cancer Care in America: Impact of State Policy on Access to High-Quality Cancer Care

View more
SHOW MORE ARTICLES

The Process of NCCN Guidelines‚Ñ¢ Adaptation to the Middle East and North Africa Region

View more

HSR20-103: Years of Potential Life Lost Due to Cervical and Uterine Cancer Deaths in the United States, 2000-2016

View more

HSR20-104: Treatment Patterns and Time Trends for Intrahepatic Cholangiocarcinoma (iCCA) Patients: A Real-World Retrospective Claims Study

View more

HSR20-105: The Impact of Gastric Cancer Clinical Pathways Based on National Comprehensive Cancer Network Guidelines on Treatment Heterogeneity and Clinical Outcomes in the US Oncology Network

View more

HSR20-106: Quantifying Patient Preferences for Attributes Associated With First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

View more

HSR20-108: Treatment Patterns and Outcomes in US Adults with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study of First-Line Treatments

View more

HSR20-110: The Promotion of Exercise Oncology as a Standard Part of Clinical Practice

View more

HSR20-111: Characteristics, Treatment Patterns, Healthcare Resource Use and Costs among Pediatric Patients Diagnosed with Neurofibromatosis Type 1 and Plexiform Neurofibromas: A Retrospective Database Analysis

View more

HSR20-114: Impact of Social Determinants of Health on Unplanned Acute Care Service Utilization for Patients With Hematologic Malignancies

View more

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018

View more

NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy

View more

Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma

View more

FAQS